Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 67

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 67
---
, shall be issued instead pre -fundedwarrants exercisable for a number of NLS Common Shares equal to such NLS Common Shares in excess of the beneficial ownership limitation, at an exercise price equal to the par value of the NLS Common Shares as of the Effective Time, which, in any event, shall be no less than CHF 0.0001 per share. 3 Expected Timing of the Merger (Page 124) The Closing is expected to take place (i) no later than the second business day following the satisfaction or waiver of the conditions described below under the section titled “ Conditions to the Consummation of the Merger” on page 123 of this proxy statement/prospectus, or (ii) on such other date as agreed to by the parties to the Merger Agreement in writing, in each case, subject to the satisfaction or waiver of the closing conditions. The Merger Agreement may be terminated by NLS and/or Kadimastem if the Closing has not occurred by April30, 2025. NLS and Kadimastem anticipate that the consummation of the Merger will occur in the second quarter of 2025. However, because the Merger is subject to a number of conditions, neither NLS nor Kadimastem can predict exactly when the Closing will occur or if it will occur at all. For a description of the conditions to the completion of the Merger, see the section titled “ Conditions to the Consummation of the Merger” on page 123 of this proxy statement/prospectus. NLS Meeting (Page 74) Date, Time and Place of the of the NLS Meeting The NLS Meeting will be held at 4 pm, local time, on, 2025, at Advokatur 107, Rorschacher Str. 107, 9000 St. Gallen, Switzerland. NLS will be hosting the NLS Meeting in person to consider and vote upon: •Proposal No. 1 to approve the Merger Agreement. •Proposal No. 2 to approve the ordinary share capital increase with contribution of the Kadimastem shares to implement the Merger. •Proposal No. 3 to approve the ordinary share capital increase regarding the issuance of preferred shares. •Proposal No. 4 to approve the reinstatement of the capital band. •Proposal No. 5 to approve the conditional share capital for employee and advisory options. •Proposal No. 6 to approve the conditional share capital for